Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | MLYCD | O95822 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL370922 | 0.87 | RAB9A (0.51) | KDM4EKMT2AMEN1CYP1A2CYP2C9 | |
| SCHEMBL13596197 | 0.86 | KMT2A (0.56) | KDM4EKMT2AMEN1CYP1A2CYP2C9 | |
| SCHEMBL23709491 | 0.84 | KDM4E (0.55) | KDM4EKMT2AMEN1CYP1A2CYP2C9 | |
| SCHEMBL24723675 | 0.84 | TSHR (0.66) | KDM4EKMT2AMEN1NPC1RAB9A | |
| SCHEMBL13009069 | 0.84 | KMT2A (0.51) | KDM4EKMT2AMEN1CYP1A2CYP2C9 | |
| SCHEMBL9891897 | 0.83 | ALDH1A1 (0.62) | KDM4EKMT2AMEN1CYP1A2CYP2C9 | |
| SCHEMBL26098377 | 0.83 | RAB9A (0.47) | KDM4EKMT2AMEN1NPC1RAB9A | |
| SCHEMBL26098374 | 0.83 | RAB9A (0.47) | KDM4EKMT2AMEN1NPC1RAB9A | |
| SCHEMBL15000367 | 0.82 | KMT2A (0.53) | KDM4EKMT2AMEN1CYP1A2CYP2C9 | |
| SCHEMBL9891902 | 0.82 | AR (0.64) | KDM4EKMT2AMEN1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130758-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-09-28 | — | — | US | disclosed |
| US-20200347050-A1 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-11-05 | — | — | US | disclosed |
| US-9850242-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD (JP) | 2017-12-26 | — | — | US | disclosed |
| EP-1856098-B1 | PYRAZINYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORP (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
| EP-1853583-B1 | AMINE-LINKED PYRIDYL AND PHENYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORP (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7879838-B2 | Chemokine receptor antagonists used for the treatment of inflammatory diseases, autoimmune diseases, transplant rejection, infectious diseases, drug sensitivity, ophthalmic inflammation, type I diabetes, viral meningitis and tumors | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879838-B2 | Chemokine receptor antagonists used for the treatment of inflammatory diseases, autoimmune diseases, transplant rejection, infectious diseases, drug sensitivity, ophthalmic inflammation, type I diabetes, viral meningitis and tumors | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| US-7868005-B2 | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868005-B2 | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2011-01-11 | — | — | US | disclosed |
| US-7776862-B2 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776862-B2 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| US-7566718-B2 | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070054919-A1 | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070021611-A1 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070021611-A1 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054919-A1 | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity | CXCR3, CXCR1, CCR5 | KDM4E 2942/4885KMT2A 3963/4885MEN1 2895/4885 |
| US-20070021611-A1 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | CXCR3, CCR1, CCR5 | KDM4E 2641/4885KMT2A 3696/4885MEN1 2504/4885 |
| US-20200347050-A1 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | SSB, TLR8, TLR9 | KDM4E 1310/4885KMT2A 2351/4885MEN1 4768/4885 |
| US-11130758-B2 | Tetrahydropyrazolopyrimidine compounds | SSB, TLR8, TLR9 | KDM4E 1310/4885KMT2A 2351/4885MEN1 4768/4885 |
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | KDM4E 3267/4885KMT2A 3647/4885MEN1 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.